Login / Signup

Safety, tolerability and immunogenicity of PRV-101, a multivalent vaccine targeting coxsackie B viruses (CVBs) associated with type 1 diabetes: a double-blind randomised placebo-controlled Phase I trial.

Heikki HyötySusanna KääriäinenJutta E LaihoGail M ComerWei TianTaina HärkönenJussi P LehtonenSami OikarinenLeena PuustinenMichele SnyderFrancisco LeónMika ScheininOlli H LaitinenMiguel Sanjuan
Published in: Diabetologia (2024)
This trial was funded by Provention Bio, a Sanofi company.
Keyphrases
  • placebo controlled
  • phase iii
  • phase ii
  • study protocol
  • open label
  • double blind
  • clinical trial
  • randomized controlled trial
  • phase ii study
  • squamous cell carcinoma
  • drug delivery
  • radiation therapy